List view / Grid view
26 April 2016 | By Victoria White, Digital Content Producer
Allergan has broken ground on a $200 million expansion of its Texas Waco facility that will nearly double its current footprint when completed...
22 April 2016 | By Victoria White, Digital Content Producer
Allergan has acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5...
6 April 2016 | By Victoria White
The decision was driven by the actions announced by the US Department of Treasury, which the companies concluded qualified as an “Adverse Tax Law Change”...
17 March 2016 | By Victoria White
Allergan believes it is a first applicant to file an ANDA for generic Abraxane and, should it be approved, may get 180 days of generic market exclusivity...
24 February 2016 | By Victoria White
Avycaz was first approved in the US in February 2015 for the treatment of adult patients with cIAI and cUTI caused by designated susceptible bacteria...
16 February 2016 | By Victoria White
If approved, this filing will expand the label of Teflaro beyond adults to include the treatment of children two months of age and older...
15 February 2016 | By Robert Yardy, Head of New Business and Marketing, MMT Digital
Robert Yardy of MMT Digital, a company that redeveloped Allergan's corporate website, discusses the value to pharmaceutical companies of having a responsive, fully functional website...
8 February 2016 | By Victoria White
The close of the transaction to combine Pfizer and Allergan is expected in the second half of 2016, and is subject to certain conditions...
29 January 2016 | By Victoria White
Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam...
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
21 January 2016 | By Victoria White
In the Phase III trials, significantly more patients treated with Viberzi experienced improvements in diarrhoea and abdominal pain, as compared with placebo...
15 December 2015 | By Victoria White
Viberzi, a twice daily, oral medication, is Allergan’s first-in-class treatment for irritable bowel syndrome with diarrhoea (IBS-D)...
25 November 2015 | By Garry White, Chief Investment Commentator, Charles Stanley
Viagra maker Pfizer announced on Monday that it would purchase Allergan, the Irish maker of Botox, for about $160bn – the biggest deal ever in the healthcare sector. Could more mega-mergers be in prospect?
23 November 2015 | By Victoria White
The combined company, to be named Pfizer plc, will be the biggest drug maker in the world by sales...
4 November 2015 | By Victoria White
Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin...
